| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 653.14% | HC Wainwright & Co. | $34 → $18 | Maintains | Buy |
| 06/02/2023 | 1322.59% | HC Wainwright & Co. | → $34 | Reiterates | → Buy |
| 03/13/2023 | 1322.59% | HC Wainwright & Co. | → $34 | Reiterates | → Buy |
| 06/24/2021 | 109.21% | Aegis Capital | → $5 | Initiates Coverage On | → Buy |
| 09/24/2019 | 25.52% | HC Wainwright & Co. | $30 → $3 | Maintains | Buy |
What is the target price for Can Fite Biofarma (CANF)?
The latest price target for Can Fite Biofarma (AMEX: CANF) was reported by HC Wainwright & Co. on October 24, 2023. The analyst firm set a price target for $18.00 expecting CANF to rise to within 12 months (a possible 653.14% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Can Fite Biofarma (CANF)?
The latest analyst rating for Can Fite Biofarma (AMEX: CANF) was provided by HC Wainwright & Co., and Can Fite Biofarma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Can Fite Biofarma (CANF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Can Fite Biofarma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Can Fite Biofarma was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
Is the Analyst Rating Can Fite Biofarma (CANF) correct?
While ratings are subjective and will change, the latest Can Fite Biofarma (CANF) rating was a maintained with a price target of $34.00 to $18.00. The current price Can Fite Biofarma (CANF) is trading at is $2.39, which is out of the analyst's predicted range.